BCM
IMGN

BlueCrest Capital Management’s Immunogen Inc IMGN Stock Holding History

BlueCrest Capital Management’s Portfolio IMGN Stock Details IMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-19,084
Closed -$41K – 683
2019
Q2 		$41K Buy
+19,084
New +$45.1K ﹤0.01% 380
2017
Q4 		– Sell
-11,420
Closed -$87K – 1158
2017
Q3 		$87K Buy
+11,420
New +$75.9K ﹤0.01% 797
2016
Q4 		– Sell
-15,817
Closed -$42K – 923
2016
Q3 		$42K Buy
+15,817
New +$46K ﹤0.01% 712

Other funds holding IMGN

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlueCrest Capital Management's IMGN Position: Q3 2019 in Review

BlueCrest Capital Management sold out of Immunogen Inc (IMGN) in Q3 2019, closing a stake of 19,084 shares — an estimated $41K sold.

BlueCrest Capital Management first reported a position in IMGN in Q3 2016 and held it in 3 quarters. The position peaked at $87K in Q3 2017. 189 funds tracked by Wall St. Rank hold IMGN as of Q3 2019.

  • BlueCrest Capital Management reported no remaining Immunogen Inc position as of Q3 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 19,084 Immunogen Inc shares in Q3 2019, an estimated $41K.
  • BlueCrest Capital Management first reported a position in Immunogen Inc in Q3 2016 and held it in 3 quarters.
  • BlueCrest Capital Management's Immunogen Inc position peaked at $87K in Q3 2017.
  • 189 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2019.

Based on BlueCrest Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.